Free radical-mediated oxidative dna damage in the mechanism of thalidomide teratogenicity

Nature Medicine

Volumn 5, Issue 5, 1999, Pages 582-585

  Parman, Toufan ^a   Wiley, Michael J ^b   Wells, Peter G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FREE RADICAL; HORSERADISH PEROXIDASE; N TERT BUTYL ALPHA PHENYLNITRONE; PROSTAGLANDIN SYNTHASE; THALIDOMIDE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; EMBRYOPATHY; INTRAGASTRIC DRUG ADMINISTRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RABBIT; SPECIES DIFFERENCE; TERATOGENICITY; XENOBIOTIC METABOLISM;

EID: 0032920883     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/8466     Document Type: Article

References (25)

1. Lenz, W. A short history of thalidomide embryopathy. Teratology 38, 203-15 (1988).
2. Castilla, E.E. et al. Thalidomide, a current teratogen in South America. Teratology 54, 273-7 (1996).
3. Stephens, T.D. Proposed mechanisms of action in thalidomide embryopathy. Teratology 38, 229-39 (1988).
4. Wells, P.G. & Winn, L.M. Biochemical toxicology of chemical teratogenesis. Crit. Rev. Biochem. Mol. Biol. 31, 1-40 (1996).
5. Parman, T., Chen, G. & Wells, P.G. Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry, and photochemical product analysis. J. Biol. Chem. 273, 25079-88 (1998).
6. Liu, L. & Wells, P.G. DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2′-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Free Radic. Biol. Med. 19, 639-48 (1995).
7. Arlen, R.R. & Wells, P.G. Extracellular thiol-disulfide status reflecting chemical toxicity mediated via oxidative stress: Validation with paraquat and t-butylhydroperoxide, and implications for phenytoin and thalidomide teratogenicity. FASEB J. 4, A608 (1990).
8. Arlen, R.R. & Wells, P.G. Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. J. Pharm. Exp. Ther. 277, 1649-58 (1996).
9. Wells, P.G., Kim, P.M., Nicol, C.J., Parman, T. & Winn, L.M. in Handbook of Experimental Pharmacology Vol. 124, Part I, Ch. 17 (eds. Kavlock, R.J. & Daston, G.P.) 453-518 (Springer-Verlag, Heidelberg, 1997).
10. Winn, L.M. & Wells, P.G. Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis. Free Radic. Biol. Med. 22, 607-21 (1997).
11. Kim, P.M. & Wells, P.G. Phenytoin-initiated hydroxyl radical formation: characterization by enhanced salicylate hydroxylation. Mol. Pharm. 49, 172-81 (1996)
12. Cheng, K.C., Cahill, D.S., Kasai, H., Nishimura, S. & Loeb, L.A. 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G - T and A - C substitutions. J. Biol. Chem. 267, 166-72 (1992).
13. Ashby, J. et al. Thalidomide: lack of mutagenic activity across phyla and genetic endpoints. Mutat. Res. 396, 45-46 (1997).
14. Schumacher, H., Smith, R.L. & Williams, R.T. The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species. Br. J. Phamacol. 25, 338-351 (1965).
15. Gordon, G.B., Spielberg, S.P., Blake, D.A. & Balasubramanian, V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Nat. Acad. Sci. USA 78, 2545-8 (1981).
16. Huang, P.H. & McBride, W.G. Interaction of [glutarimide-2-14C]-thalidomide with rat embryonic DNA in vivo [see comments]. Teratogen. Carcinogen. Mutagen. 17, 1-5 (1997).
17. Neubert, D. Never-ending tales of the mode of the teratogenic action of thalidomide. Teratogen. Carcinogen. Mutagen. 17, i-ii (1997).
18. Braun, A.G., Harding, F.A. & Weinreb, S.L. Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol. Appl. Pharm. 82, 175-9 (1986).
19. Hatfill, S.J., Fester, E.D., de Beer, D.P. & Bohm, L. Induction of morphological differentiation in the human leukemic cell line K562 by exposure to thalidomide metabolites. Leukemia Res. 15, 129-36 (1991).
20. Jonsson, N.A. Chemical structure and teratogenic properties 3. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogues. Acta Pharma. Suec. 9, 521-42 (1972).
21. Wuest, H.M., Fox, R.R. & Crary, D.D. Relationship between teratogenicity and structure in the thalidomide field. Experientia 24, 993-4 (1968).
22. Kitada, M. & Kamataki, T. Cytochrome P450 in human fetal liver: significance and fetal-specific expression. Drug Metab. Rev. 26, 305-23 (1994).
23. Pottenger, L.H. & Jefcoate, C.R. Characterization of a novel cytochrome P450 from the transformable cell line, C3H/10T1/2. Carcinogenesis 11, 321-7 (1990).
24. Yang, H.Y., Lee, Q.P., Rettie, A.E. & Juchau, M.R. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol. Pharmacol. 46, 922-8 (1994).
25. Winn, L.M. & Wells, P.G. Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity. Free Radic. Biol. Med. 26, 266-74 (1999).